Overview: Anti-Mullerian Hormone TestIntroduction: The Anti-Mullerian Hormone Test measures AMH levels to assess ovarian reserve, helping evaluate fertility or conditions like polycystic ovary syndrome that affect menstruation. Following 2023 ASRM guidelines, it uses an immunoassay for high sensitivity, aiding in endocrine screening. This test is critical for guiding fertility treatment, monitoring ovarian function, and improving outcomes in endocrinology for patients with fertility concerns.
Other Names: AMH Assay, Ovarian Reserve Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: AMH testing began in the 1990s for fertility assessment. Immunoassays emerged in the 2000s, and by the 2010s, high-sensitivity assays improved ovarian reserve evaluation.
Purpose: Assesses ovarian reserve, guides fertility treatment, and diagnoses conditions like PCOS in patients with irregular menstruation or infertility.
Test Parameters: 1. Anti Mullerian Hormone
Pretest Condition: Fasting for 10-12 hours required to stabilize hormone levels. Collect serum or plasma after overnight fasting. Report symptoms like irregular periods or infertility, and list medications like hormonal contraceptives.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document menstrual irregularities, infertility, or family history of ovarian disorders. Include current medications, especially hormonal contraceptives or fertility drugs.
Consent: Written consent required, detailing the tests purpose, implications for fertility planning, and potential need for further testing or treatment.
Procedural Considerations: Uses an immunoassay to measure AMH levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or hormonal contraceptives may alter results. Hemolysis or improper storage can degrade samples.
Clinical Significance: Low AMH levels indicate reduced ovarian reserve, prompting fertility interventions. High levels suggest PCOS, requiring further evaluation.
Specialist Consultation: Consult a reproductive endocrinologist for result interpretation. A gynecologist referral is advised for PCOS management.
Additional Supporting Tests: FSH test, antral follicle count, or pelvic ultrasound to confirm ovarian reserve or diagnose PCOS.
Test Limitations: AMH levels vary with age and may not predict pregnancy outcomes. Results require clinical correlation.
References: ASRM Fertility Guidelines, 2023; Fertility and Sterility, Broekmans FJ, 2022.
